A Study Evaluating 10 mg and 25 mg Doses of Etanercept in Patients With Rheumatoid Arthritis
NCT ID: NCT00484237
Last Updated: 2007-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
80 participants
INTERVENTIONAL
2007-04-30
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
etanercept
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Inadequate response to at least one disease modifying anti-rheumatic drug (DMARD)
* Have not been treated with a DMARD for at least 4 weeks prior to the baseline visit
Exclusion Criteria
* Received investigational drugs within 6 months of the baseline visit
* Received intra-articular hyaluronic acid injections within 4 weeks of the baseline visit
20 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Goshogawara, Aomori, Japan
Choseigun, Chiba, Japan
Yotsukaidō, Chiba, Japan
Fukuoka, Fukuoka, Japan
Fukushima, Fukushima, Japan
Higashihiroshima, Hiroshima, Japan
Katoh, Hyōgo, Japan
Sagamihara, Kanagawa, Japan
Kumamoto, Kumamoto, Japan
Sendai, Miyagi, Japan
Nagano, Nagano, Japan
Sasebo, Nagasaki, Japan
Ōita, Oita Prefecture, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0881A1-3324
Identifier Type: -
Identifier Source: org_study_id